EMJ Hematology最新文献_第9页

Bridging to Transplant in Diffuse Large B Cell Lymphoma 弥漫性大B细胞淋巴瘤的桥接移植

EMJ Hematology Pub Date : 2016-07-26 DOI: 10.33590/emjhematol/10310457

C. Gisselbrecht, E. Van Den Neste

{"title":"Bridging to Transplant in Diffuse Large B Cell Lymphoma","authors":"C. Gisselbrecht, E. Van Den Neste","doi":"10.33590/emjhematol/10310457","DOIUrl":"https://doi.org/10.33590/emjhematol/10310457","url":null,"abstract":"Non-Hodgkin lymphoma (NHL) is the eighth most common malignancy worldwide. Diffuse large B cell lymphoma (DLBCL) is the most frequent subtype, accounting for >30% of NHL cases. Advances in novel approaches in the last two decades, such as immunotherapy with rituximab, have achieved improvements in terms of overall and long-term survival rates. The current standard of care for the first-line treatment of DLBCL is chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone; this regimen achieves complete and sustained remission in approximately 60% of patients. Nevertheless, DLBCL relapses in 30–40% of patients, of which 10% develop refractory disease. Recent findings have demonstrated that substantial responses could be achieved after second or third-line treatments with combined chemotherapy. Since 2012, the aza-anthracenedione, pixantrone, has been approved as a single agent for relapsed or refractory DLBCL. The drug could be a new option as a bridging therapy to consolidate autologous or allogeneic stem cell transplantation, which in turn, can deliver prolonged durations of remission. Numerous clinical studies are ongoing that aim to improve salvage rates, outcomes, and access to stem cell transplantations for relapsed or refractory DLBCL. The development of novel targeted therapies or chemotherapeutics, such as pixantrone, will help to salvage more patients and achieve further sustained and complete responses without compromising their quality of life.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124122943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

New Insights in Bone Marrow Failure 骨髓衰竭的新见解

EMJ Hematology Pub Date : 2016-06-28 DOI: 10.33590/emjhematol/10312028

Joan Thomas

引用次数: 0

Advancing Our Clinical Perspectives in Haematology: What Is Your Approach? 推进血液学的临床前景:你的方法是什么?

EMJ Hematology Pub Date : 2016-06-16 DOI: 10.33590/emjhematol/10311643

Shire

引用次数: 0

Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond 2015年及以后套细胞淋巴瘤和滤泡性淋巴瘤的治疗展望

EMJ Hematology Pub Date : 2015-07-30 DOI: 10.33590/emjhematol/10312591

Juliette B. Bell

引用次数: 0

EMJ Hematology Pub Date : 2015-07-30 DOI: 10.33590/emjhematol/10311696

Lynda M. McEvoy

引用次数: 0

Relapsed/Refractory Multiple Myeloma: The Current State of Play 复发/难治性多发性骨髓瘤:目前的发展状况

EMJ Hematology Pub Date : 2015-07-30 DOI: 10.33590/emjhematol/10314714

M. Mateos, E. Ocio, V. Gonzalez, J. Dávila

{"title":"Relapsed/Refractory Multiple Myeloma: The Current State of Play","authors":"M. Mateos, E. Ocio, V. Gonzalez, J. Dávila","doi":"10.33590/emjhematol/10314714","DOIUrl":"https://doi.org/10.33590/emjhematol/10314714","url":null,"abstract":"Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone or in combination, followed by an autologous stem cell transplant (ASCT). Usually only clinical relapses require treatment; the treatment plan should be individualised to take into account factors such as response to previous treatment, duration of the remission, adverse effects experienced, and available treatment options. Evidence suggests that many patients who have responded to BOR will respond to it again. Patients at first relapse should also be considered for a further ASCT or an allotransplant. Clinical studies have led to other drugs being approved for treatment of relapsed MM. These include lenalidomide (an immunomodulatory drug), carfilzomib (another proteasome inhibitor), pomalidomide (an immunomodulatory drug), and most recently panobinostat (a deacetylase inhibitor). The availability of these drugs greatly enhances the therapeutic options available to treat further relapses. Moreover, a bewildering array of other novel agents are at various stages in testing. They include other drugs from the classes already mentioned, as well as monoclonal antibodies, drugs acting on the cell cycle, kinase inhibitors, and signal transduction pathway inhibitors. It seems probable that the introduction of these agents in the coming years will further improve the survival of patients with MM, and may even lead to a cure.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131353083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombosis in Haematological Disorders: Tailored Management Approaches 血液病中的血栓形成:量身定制的管理方法

EMJ Hematology Pub Date : 2015-07-30 DOI: 10.33590/emjhematol/10312317

Saroshi Amirthalingam

引用次数: 0

Biosimilars in Hematology: Increasing Choice, Expanding Access 血液学生物仿制药:增加选择，扩大获取

EMJ Hematology Pub Date : 2014-07-31 DOI: 10.33590/emjhematol/10310005

Tom Priddle

{"title":"Biosimilars in Hematology: Increasing Choice, Expanding Access","authors":"Tom Priddle","doi":"10.33590/emjhematol/10310005","DOIUrl":"https://doi.org/10.33590/emjhematol/10310005","url":null,"abstract":"Biologicals have revolutionised modern medicine by offering vital therapeutic options to treat or prevent complex, disabling, and life-threatening diseases. Between 2013 and 2018, seven of the top ten pharmaceuticals worldwide will be biologicals; however, growing demand, combined with historically-limited competition, will continue to strain healthcare budgets and limit patient access to these treatments. Since 2006, when the first biosimilar Omnitrope® was approved in Europe, 18 other biosimilars, including the first biosimilar monoclonal antibody (mAb), infliximab (approved in 2013), have received marketing authorisation with many others currently in development. There is now extensive clinical experience with biosimilar epoetin (EPO) and filgrastim in patients with cancer, and many studies have reported comparable efficacy with the originator products, no unexpected safety concerns, and significant economic savings. Nevertheless, misconceptions concerning biosimilars remain. This educational session discussed these issues and gave an overview of biosimilar use in hematology. Dr Joerg Windisch highlighted the particular challenges and considerations associated with the development of biosimilars while Prof Steffen Thirstrup covered the approval of biosimilars from the regulatory perspective. Dr Wojciech Jurczak gave a presentation on the development of biosimilars in hematology, with a particular focus on rituximab from a clinical perspective. Dr Paul Cornes concluded with the opportunities that the introduction of biosimilars offer in terms of health economics and improved patient access to care.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123996040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Iron Supplementation for Perioperative Anaemia in Patient Blood Management 补铁治疗围手术期贫血患者血液管理

EMJ Hematology Pub Date : 2014-07-31 DOI: 10.33590/emjhematol/10312664

M. Muñoz, S. Gómez‐Ramírez, A. Campos

{"title":"Iron Supplementation for Perioperative Anaemia in Patient Blood Management","authors":"M. Muñoz, S. Gómez‐Ramírez, A. Campos","doi":"10.33590/emjhematol/10312664","DOIUrl":"https://doi.org/10.33590/emjhematol/10312664","url":null,"abstract":"In patients undergoing major surgical procedures, preoperative anaemia and perioperative allogeneic blood transfusion (ABT) have been linked to increased postoperative morbidity and mortality, as well as longer hospital stays. A multidisciplinary, multimodal, individualised strategy – collectively termed patient blood management – used to minimise or eliminate ABT is indicated to improve outcomes. This new standard of care relies on detection and treatment of perioperative anaemia (Pillar 1) and reduction of surgical blood loss and perioperative coagulopathy (Pillar 2) to harness and optimise physiological tolerance of anaemia (Pillar 3), thus allowing the use of restrictive transfusion criteria. Normalisation of preoperative hemoglobin levels is a World Heath Organization recommendation. Iron repletion should be routinely ordered when indicated. Preoperative oral iron is time-consuming and poorly tolerated with low adherence in published trials. Postoperative oral iron has been proven to be inefficacious and is no longer recommended. Preoperative and perioperative intravenous iron, with or without erythropoiesis stimulating agents, is safe and effective at reducing ABT rate and hastening the recovery from postoperative anaemia. Intravenous iron does not seem to increase the risk for postoperative thromboembolism, infection, or mortality. Newer intravenous iron formulations demonstrate potentially much lower immunogenic activity, allow complete replacement dosing in 15 to 60 minutes, markedly facilitating care, and may be cost-effective in many clinical settings.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127238408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Looking Back To Our Roots: 80 Years of Wintrobe’s Indices 回顾我们的根源:Wintrobe指数的80年

EMJ Hematology Pub Date : 2014-07-31 DOI: 10.33590/emjhematol/10310807

E. Urrechaga, S. Izquierdo, J. Escanero

{"title":"Looking Back To Our Roots: 80 Years of Wintrobe’s Indices","authors":"E. Urrechaga, S. Izquierdo, J. Escanero","doi":"10.33590/emjhematol/10310807","DOIUrl":"https://doi.org/10.33590/emjhematol/10310807","url":null,"abstract":"This year (2014) we are celebrating the 80th anniversary of Dr Maxwell Myer Wintrobe’s pioneer works, one of the most important contributions in clinical laboratory and medicine. Red cell indices continue to provide an essential support to the diagnosis and classification of anaemia. The erythrocyte indices, such as mean cell volume, mean cell hemoglobin concentration, and mean cell hemoglobin, are called the Wintrobe’s indices. Automation in hematology has progressed steadily since Wallace Coulter first applied electrical impedance technology to counting red cells and white cells. Technological advances being incorporated into hematology analysers since then are now allowing access to more cellular information than was ever available before through a ‘simple routine complete blood count’. Current research is beginning to demonstrate that this information also has great potential to identify cellular changes that typically occur in several important medical conditions-bringing us all one step closer to using hematology analysers as more than just simple cell counters, but instead as powerful tools for the management of any medical condition that impacts the biology of blood cells. There are increasing amounts of data provided, which require specialist knowledge to interpret as well as to understand the limitations in the measurement of the parameter. Both laboratory scientists and clinicians need to keep up-to-date with new parameters and methods in hematology, implying a stronger collaboration between them to improve clinical decision-making.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125825508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2